Modulation of the TRPV1 channel: Current clinical trials and recent patents with focus on neurological conditions

Recent Patents on CNS Drug Discovery

Volumn 8, Issue 3, 2013, Pages 180-204

  De Petrocellis, Luciano ^a   Moriello, Aniello S ^a  

^a CNR   (Italy)

Author keywords

Inflammation; Pain; TRPV1

Indexed keywords

CAPSAICIN; PARTIAL AGONIST; PIPERINE; RESINIFERATOXIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UREA DERIVATIVE; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 AGONIST; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR AGONIST;

ANALGESIC ACTIVITY; CLINICAL TRIAL (TOPIC); HUMAN; INFLAMMATORY PAIN; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW;

ANALGESICS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PAIN; PATENTS AS TOPIC; TRPV CATION CHANNELS;

EID: 84892492983     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574889808666131209124012     Document Type: Review

References (282)

1. Venkatachalam K, Montell C. TRP channels. Annu Rev Biochem 2007; 76: 387-417.
2. Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: Targeting pain at the source. Nat Rev Drug Discov 2009; 8: 55-68.
3. Lishko PV, Procko E, Jin X, Phelps CB, Gaudet R. The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 2007; 54: 905-18.
4. Clapham DE, Runnels, LW, Strubing C. The TRP ion channel family. Nature Rev Neurosci 2001; 2: 387-96
5. Moran MM, McAlexander MA, Biro T, Szallasi A. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov 2011; 10: 601-20.
6. Voets T, Nilius B. Modulation of TRPs by PIPs. J Physiol 2007; 582: 939-44.
7. Nilius B, Owsianik G. Transient receptor potential channelopathies. Pflugers Arch 2010; 460: 437-50.
8. Colbert HA, Smith TL, Bargmann CI. OSM-9, a novel protein with structural similarity to channels, is required for olfaction, mechanosensation, and olfactory adaptation in Caenorhabditis elegans. J Neurosci 1997; 17: 8259-69.
9. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997; 389: 816-24.
10. Jara-Oseguera A, Simon SA, Rosenbaum T. TRPV1: On the road to pain relief. Curr Mol Pharmacol 2008; 1: 255-69.
11. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267-84.
12. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Sci 2000; 288: 306-13.
13. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000; 405: 183-7.
14. Baccei ML, Bardoni R, Fitzgerald M. Development of nociceptive synaptic inputs to the neonatal rat dorsal horn: Glutamate release by capsaicin and menthol. J Physiol 2003; 549: 231-42.
15. Sikand P, Premkumar LS. Potentiation of glutamatergic synaptic transmission by protein kinase C-mediated sensitization of TRPV1 at the first sensory synapse. J Physiol 2007; 581: 631-47.
16. Jeffry JA, Yu SQ, Sikand P, Parihar A, Evans MS, Premkumar LS. Selective targeting of TRPV1 expressing sensory nerve terminals in the spinal cord for long lasting analgesia. PLoS One 2009; 4: e7021.
17. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neurosci 2006; 139: 1405-15.
18. Sanchez JF, Krause JE, Cortright DN. The distribution and regulation of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat. Neurosci 2001; 107: 373-81.
19. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F, Maione S. Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain 2010; 6: 66
20. Doyle MW, Bailey TW, Jin YH, Andresen MC. Vanilloid receptors presynaptically modulate cranial visceral afferent synaptic transmission in nucleus tractus solitarius. J Neurosci 2002; 129: 195-209
21. Marinelli S, Vaughan CW, Christie MJ, Connor M. Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 2002; 543: 531-40.
22. Marinelli S, Di Marzo V, Berretta N, Matias I, Maccarrone M, Bernardi G, et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J Neurosci 2003; 23: 3136-44.
23. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA. TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 2008, 57: 746-59.
24. Chávez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci 2010; 13: 1511-8.
25. Grueter BA, Brasnjo G, Malenka RC. Postsynaptic TRPV1 triggers cell type-specific long-term depression in the nucleus accumbens. Nat Neurosci 2010; 13: 1519-25.
26. Cavanaugh DJ, Chesler AT, Jackson AC, Sigal YM, Yamanaka H, Grant R, et al. Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J Neurosci 2011; 31: 5067-77.
27. Goswami C, Rademacher N, Smalla KH, Kalscheuer V, Ropers HH, Gundelfinger ED, et al. TRPV1 acts as a synaptic protein and regulates vesicle recycling. J Cell Sci 2010; 123: 2045-57.
28. Yang K, Kumamoto E, Furue H, Yoshimura M. Capsaicin facilitates excitatory but not inhibitory synaptic transmission in substantia gelatinosa of the rat spinal cord. Neurosci Lett 1998; 255: 135-8.
29. Ferrini F, Salio C, Vergnano AM, Merighi A. Vanilloid receptor-1 (TRPV1)-dependent activation of inhibitory neurotransmission in spinal substantia gelatinosa neurons of mouse. Pain 2007; 129: 195-209.
30. El Andaloussi-Lilja J, Lundqvist J, Forsby A. TRPV1 expression and activity during retinoic acid-induced neuronal differentiation. Neurochem Int 2009; 55: 768-74.
31. Sappington RM, Sidorova T, Long DJ, Calkins DJ. TRPV1: Contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure. Invest Ophthalmol Vis Sci 2009; 50: 717-28.
32. Liu M, Liu MC, Magoulas C, Priestley JAV, Willmott NJ. Versatile regulation of cytosolic Ca2+ by vanilloid receptor-1 in rat dorsal root ganglion neurons. J Biol Chem 2003; 278: 5462-72.
33. Marshall ICB, Owen DE, Cripps TV, Davis JB, McNulty S, Smart D. Activation of vanilloid receptor 1 by resiniferatoxin mobilizes calcium from inositol 1,4,5-triphosphate-sensitive stores. Br J Pharmacol 2003; 138: 172-6.
34. Doly S, Fischer J, Salio C, Conrath M. The vanilloid receptor-1 is expressed in rat spinal dorsal horn astrocytes. Neurosci Lett 2004; 357: 123-6.
35. Sappington RM, Calkins DJ. Contribution of TRPV1 to microgliaderived IL-6 and NFkappaB translocation with elevated hydrostatic pressure. Invest Ophthalmol Vis Sci 2008; 49: 3004-17.
36. Cuypers E, Yanagihara A, Karlsson E, Tytgat J. Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels. FEBS Lett 2006; 580: 5728-32.
37. Siemens J, Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, et al. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 2006; 444: 208-12.
38. Bohlen CJ, Priel A, Zhou S, King D, Siemens J, Julius D. A bivalent tarantula toxin activates the capsaicin receptor, TRPV1, by targeting the outer pore domain. Cell 2010; 141: 834-45.
39. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
40. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agrò A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001; 276: 12856-63.
41. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 99: 8400-5.
42. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, et al. N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 2003; 278: 13633-9.
43. De Petrocellis L, Chu CJ, Schiano MA, Kellner JC, Walker JM, Di Marzo V. Actions of two naturally occurring saturated Nacyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. Br J Pharmacol 2004; 143: 251-6.
44. Ahern GP. Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 2003; 278: 30429-34.
45. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPAR_ agonist palmitoylethanolamide. Br J Pharmacol 2013; 168: 1430-44.
46. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: Endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000; 97: 6155-60.
47. Wen H, Östman J, Bubb KJ, Panayiotou C, Priestley JV, Baker MD, et al. 20-Hydroxyeicosatetraenoic acid (20-HETE) is a novel activator of transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 2012; 287: 13868-76.
48. De Petrocellis L, Schiano Moriello A, Imperatore R, Cristino L, Starowicz K, Di Marzo V. A re-evaluation of 9-HODE activity at TRPV1 channels in comparison to anandamide: enantioselectivity and effects at other TRP channels and in sensory neurons. Br J Pharmacol 2012; 167: 1643-51.
49. Starowicz K, Makuch W, Korostynski M, Malek N, Slezak M, Zychowska M, et al. Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS One 2013; 8: e60040.
50. Ahern GP, Wang X, Miyares RL. Polyamines are potent ligands for the capsaicin receptor TRPV1. J Biol Chem 2006; 281: 8991-5.
51. Puntambekar P, Van Buren J, Raisinghani M, Premkumar LS, Ramkumar V. Direct interaction of adenosine with the TRPV1 channel protein. J Neurosci 2004; 24: 3663-71.
52. Trevisani M, Smart D, Gunthorpe MJ, Tognetto M, Barbieri M, Campi B, et al. Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci 2002; 5: 546-51.
53. Movahed P, Jönsson BA, Birnir B, Wingstrand JA, Jørgensen TD, Ermund A, et al. Endogenous unsaturated C18 Nacylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem 2005; 280: 38496-504.
54. De Petrocellis L, Di Marzo V. Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sci 2005; 77: 1651-66.
55. Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F, et al. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 2007; 27: 13739-49.
56. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005; 24: 4211-23.
57. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000; 408: 985-90.
58. Chuang H-H, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001; 411: 957-62.
59. Mohapatra DP, Nau C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 2003; 278: 50080-90.
60. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, et al. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat Med 2010; 16: 592-7.
61. Park CK, Xu ZZ, Liu T, Lü N, Serhan CN, Ji RR. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: Distinct roles of resolvin D1, D2, and E1. J Neurosci 2011; 31: 18433-8.
62. Rohacs T, Thyagarajan B, Lukacs V. Phospholipase C mediated modulation of TRPV1 channels. Mol Neurobiol 2008; 37: 153-63.
63. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon SE. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGFstimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 2006; 128: 509-22.
64. Jung J, Shin JS, Lee SY, Hwang SW, Koo J, Cho H, et al. Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding. J Biol Chem 2004; 279: 7048-54.
65. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002; 35: 721-31.
66. Mohapatra DP, Nau C. Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMPdependent protein kinase. J Biol Chem 2005; 280: 13424-32.
67. Koplas PA, Rosenberg RL, Oxford GS. The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J Neurosci 1997; 17: 3525-37.
68. Sanz-Salvador L, Andres-Borderia A, Ferrer-Montiel A, Planells-Cases R. Agonist-and Ca2+-dependent desensitization of TRPV1 targets the receptor to lysosomes for degradation. J Biol Chem 2012; 287: 19462-71.
69. Zhu W, Xu P, Cuascut FX, Hall AK, Oxford GS. Activin acutely sensitizes dorsal root ganglion neurons and induces hyperalgesia via PKC-mediated potentiation of transient receptor potential vanilloid I. J Neurosci 2007; 27: 13770-80.
70. Tominaga M, Wada M, Masu M. Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci USA 2001; 98: 6951-6.
71. Kwak J, Wang MH, Hwang SW, Kim TY, Lee SY, Oh U. Intracellular ATP increases capsaicin-activated channel activity by interacting with nucleotide-binding domains. J Neurosci 2000; 20: 8298-304.
72. Morales-Lázaro SL, Simon, SA, Rosenbaum T. The role of endogenous molecules in modulating pain through transient receptor potential vanilloid 1 (TRPV1). J Physiol 2013; 591: 3109-21.
73. Mizumura K, Sugiura T, Katanosaka K, Banik RK, Kozaki Y. Excitation and sensitization of nociceptors by bradykinin: What do we know? Exp Brain Res 2009; 196: 53-65.
74. Lukacs V, Yudin Y, Hammond GR, Sharma E, Fukami K, Rohacs T. Distinctive Changes in plasma membrane phosphoinositides underlie differential regulation of TRPV1 in nociceptive neurons. J Neurosci 2013; 33: 11451-63.
75. Kim BM, Lee SH, Shim WS, Oh U. Histamine-induced Ca2+ influx via the PLA2/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci Lett 2004; 361: 159-62.
76. Sugiuar T, Bielefeldt K, Gebhart GF. TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J Neurosci 2004; 24: 9521-30.
77. Van Buren JJ, Bhat S, Rotello R, Pauza ME, Premkumar LS. Sensitization and translocation of TRPV1 by insulin and IGF-I. Mol Pain 2005; 1: 17.
78. Shu X, Mendell LM. Nerve growth factor acutely sensitizes the response of adult rat sensory neurons to capsaicin. Neurosci Lett 1999; 274: 159-62.
79. Zhu W, Oxford GS. Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci 2007; 34: 689-700.
80. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, et al. Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 2004; 24: 4300-12.
81. Dai Y, Moriyama T, Higashi T, Togashi K, Kobayashi K, Yamanaka H, et al. Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 2004; 24: 4293-99.
82. Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004; 279: 25665-72.
83. Cui M, Nicol GD. Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons. Neurosci 1995; 66: 459-66.
84. De Petrocellis L, Harrison S, Bisogno T, Tognetto M, Brandi I, Smith GD, et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem 2001; 77: 1660-3.
85. Mallet C, Barrière DA, Ermund A, Jönsson BA, Eschalier A, Zygmunt PM, et al. TRPV1 in brain is involved in acetaminopheninduced antinociception. PLoS One 2010; 5: e12748.
86. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolasedependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005; 280: 31405-12.
87. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000; 483: 52-6.
88. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F, et al. Reduced anxiety, conditioned fear, and hippocampal longterm potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007; 27: 832-9.
89. Ho KW, Ward NJ, Calkins DJ. TRPV1: A stress response protein in the central nervous system. Am J Neurodegener Dis 2012; 1: 1-14.
90. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, et al. Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils. Br J Pharmacol 2005; 144: 727-35.
91. Veldhuis WB, van der Stelt M, Wadman MW, van Zadelhoff G, Maccarrone M, Fezza F, et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: Role of vanilloid receptors and lipoxygenases. J Neurosci 2003; 23: 4127-33.
92. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 2003; 84: 1097-109.
93. Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur J Pharmacol 2001; 420: 123-31.
94. Ferrer-Montiel A, Fernández-Carvajal A, Planells-Cases R, Fernández-Ballester G, González-Ros JM, Messeguer A, et al. Advances in modulating thermosensory TRP channels. Expert Opin Ther Pat 2012; 22: 999-1017.
95. Kort ME, Kym PR. TRPV1 antagonists: Clinical setbacks and prospects for future development. Prog Med Chem 2012; 51: 57-70.
96. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006; 26: 9385-93.
97. Premkumar LS, Abooj M. TRP channels and analgesia. Life Sci 2013; 92: 415-24
98. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013; 716: 61-76.
99. Noto C, Pappagallo M, Szallasi A. NGX-4010, a highconcentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs 2009; 10: 702-10.
100. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00875537 (Accessed on: November 25, 2013).
101. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01886313 (Accessed on: November 25, 2013).
102. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01341548 (Accessed on: November 25, 2013).
103. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01762228 (Accessed on: November 25, 2013).
104. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01777672 (Accessed on: November 25, 2013).
105. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00804154 (Accessed on: November 25, 2013).
106. Buck, S.H., Herman, R.M., Porreca, F. Composition and method for neural desensitization. WO1990014083 (1990).
107. Iadarola, M.J., Karai, L., Olah, Z. Molecular neurochirurgerie for pain control administering locally capsaicin or resiniferatoxin. WO2002076444 (2002).
108. Iadarola MJ, Mannes AJ. The vanilloid agonist resiniferatoxin for interventional-based pain control. Curr Top Med Chem 2011; 11: 2171-9.
109. Premkumar, L.S., Springfield, I.L. Treatment of pain with resiniferatoxin and related analogs. US20090209633 (2009).
110. Roberts JC, Davis JB, Benham CD. [3H] Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 protein distribution. Brain Res 2004; 995: 176-83.
111. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, et al. Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 2004; 279: 20283-95.
112. Jung J, Hwang SW, Kwak J, Lee SY, Kang CJ, Kim WB, et al. Capsaicin binds to the intracellular domain of the capsaicinactivated ion channel. J Neurosci 1999; 19: 529-38.
113. Jung J, Lee SY, Hwang SW, Cho H, Shin J, Kang YS, et al. Agonist recognition sites in the cytosolic tails of vanilloid receptor 1. J Biol Chem 2002; 277: 44448-54.
114. De Petrocellis L, Guida F, Schiano Moriello A, De Chiaro M, Piscitelli F, de Novellis V, et al. N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacol Res 2011; 63: 294-9.
115. Giannantoni A, Mearini E, Di Stasi SM, Costantini E, Zucchi A, Mearini L, et al. New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 2004; 56: 79-87.
116. Chuang, H.-h. Methods for selective silencing of sensory neurons. US20130102680 (2013).
117. Binshtok AM, Bean BP, Woolf CJ. Inhibition of nociceptors by TRPV1-mediated entry of impermeant sodium channel blockers. Nature 2007; 449: 607-10.
118. Valiyaveetil FI, Leonetti M, Muir TW, Mackinnon R. Ion selectivity in a semisynthetic K+ channel locked in the conductive conformation. Sci 2006; 314: 1004-7.
119. Thompson, S.K., Smith, R.A., Gupta, S., Priestley, T., Laping, N.J., Saha, A.K., Rudra, S. Cyclohexylamines. WO2013063127 and US20130101667 (2013).
120. Bean, B.P., Woolf, C.J. Permanently charged sodium and calcium channel blockers as anti-inflammatory agents. US20120172429 (2012).
121. Oki, K., Tsuji, F., Setoguchi, C., Seki, I., Murai, M., Sasano, M. Method for treating a trpv1-mediated disease. US20130090359 (2013).
122. Voight EA, Kort ME. Transient receptor potential vanilloid-1 antagonists: A survey of recent patent literature. Expert Opin Ther Pat 2010; 20: 1107-22.
123. Szolcsányi J, Pintér E. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia. Expert Opin Ther Targets 2013; 17: 641-57.
124. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008; 136: 202-10.
125. Romanovsky AA, Almeida MC, Garami A, Steiner AA, Norman MH, Morrison SF, et al. The transient receptor potential vanilloid-1 channel in thermoregulation: A thermosensor it is not. Pharmacol Rev 2009; 61: 228-61.
126. Shimizu I, Iida T, Horiuchi N, Caterina MJ. 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther 2005; 314: 1378-85.
127. Honore P, Chandran P, Hernandez G, Gauvin DM, Mikusa JP, Zhong C, et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 2009; 142: 27-35.
128. Garami A, Pakai E, Oliveira DL, Steiner AA, Wanner SP, Almeida MC, et al. Thermoregulatory phenotype of the Trpv1 knockout mouse: Thermoeffector dysbalance with hyperkinesis. J Neurosci 2011; 31: 1721-33.
129. Nash MS, McIntyre P, Groarke A, Lilley E, Culshaw A, Hallett A, et al. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1Hpyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity. J Pharmacol Exp Ther 2012; 342: 389-98.
130. Reilly RM, McDonald HA, Puttfarcken PS, Joshi SK, Lewis L, Pai M, et al. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J Pharmacol Exp Ther 2012; 342: 416-28.
131. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: Targeting a pivotal point in the pain pathway. Drug Discov Today 2009; 14: 56-67.
132. Szallasi A, Sheta M. Targeting TRPV1 for pain relief: limits, losers and laurels. Expert Opin Investig Drugs 2012; 21: 1351-69.
133. Rami, H.R., Thompson, M., Wyman, P.A. Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. WO2003022809 (2003).
134. Rami HK, Thompson M, Stemp G, Fell S, Jerman JC, Stevens AJ, et al. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006; 16: 3287-91.
135. Chizh BA, O'Donnell MB, Napolitano A, Wang J, Brooke AC, Aylott MC, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007; 132: 132-41.
136. Bountra, C., Denyer, J.C. The trpvl antagonist sb-705498 for treating rhinitis. WO201026129 (2010).
137. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT0269022 (Accessed on: November 25, 2013).
138. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT0281684 (Accessed on: November 25, 2013).
139. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00461682 (Accessed on: November 25, 2013).
140. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT01424514 (Accessed on: November 25, 2013).
141. Macdonald, G.J., Mitchell, D.J., Rami, H.K., Thompson, M., Trouw, L.S., Westaway, S.M. Carboxamide derivatives. WO2004072069 (2004).
142. Westaway SM, Thompson M, Rami HK, Stemp G, Trouw LS, Mitchell DJ, et al. Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg Med Chem Lett 2008; 18: 5609-13.
143. Rami HK, Thompson M, Wyman P, Jerman JC, Egerton J, Brough S, et al. Discovery of small molecule antagonists of TRPV1. Bioorg Med Chem Lett 2004; 14: 3631-4.
144. Biggadike, K., Birault, V., Champigny, A.C., Coe, D.M., Hughes, O.R., Needham, D., Tape, D.T. Imidazo [1, 2-a] pyridine and pyrazolo [1,5-a] pyridine derivatives as trpv1 antagonists. WO2012045729 (2012).
145. Biggadike, K., Birault, V., Champigny, A.C., Coe, D.M., Hughes, O.R., Needham, D., Tape, D.T. N-cyclobutyl-imidazopyridine or-pyrazolopyridine carboxamides as trpv1 antagonists. WO2012072512 (2012).
146. Biggadike, K., Bravi, G., Champigny, A.C., Coe, D.M., Needham, D., Tape, D.T. N-cyclobutyl-imidazopyridine-methylamine as trpv1 antagonists. WO2012139963 (2012).
147. El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, et al. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther 2005; 314: 400-9.
148. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovsky AA. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J Neurosci 2010; 30: 1435-40.
149. Chen, N., Chkrabarti, P.P., Doherty, E.M., Dominguez, C., Falsey, J.R., Fotsh, C.H., Hulme, C., Katon, J., Nixey, T., Norman, M.H., Ognyanov, V.I., Pettus, L.H., Rzasa, R.M., Stec, M., Wang, H.-L., Zhu, J. Vanilloid receptor ligands and their use in treatments. WO2004014871 (2004).
150. Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, et al. Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2,3-dihydro-1H inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008; 326: 218-29.
151. Watabiki T, Kiso T, Kuramochi T, Yonezawa K, Tsuji N, Kohara A, et al. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect. J Pharmacol Exp Ther 2011; 336: 743-50.
152. Watabiki T, Kiso T, Tsukamoto M, Aoki T, Matsuoka N. Intrathecal administration of AS1928370, a transient receptor potential vanilloid 1 antagonist, attenuates mechanical allodynia in a mouse model of neuropathic pain. Biol Pharm Bull 2011; 34: 1105-8.
153. Brown, W., Johnstone, S., Labrecque, D. Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders. WO2008018827 and EP2051967 (2009).
154. Quiding H, Jonzon B, Svensson O, Webster L, Reimfelt A, Karin A, et al. TRPV1 antagonistic analgesic effect: A randomized study of AZD1386 in pain after third molar extraction. Pain 2013; 154: 808-12.
155. Gharat, L.A., Joshi, U.M., Joshi, N.K. Substituted benzofused derivatives and their use as vanilloid receptor ligands. WO2007042906 (2007).
156. Charrua A, Cruz CD, Narayanan S, Gharat L, Gullapalli S, Cruz F, et al. GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol 2009; 181: 379-86.
157. Santos-Silva A, Charrua A, Cruz CD, Gharat L, Avelino A, Cruz F. Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Auton Neurosci 2012; 166: 35-8.
158. Bakthavatchatam, R., Blum, C.A., Brielmann, H.L., Timothy, M., Caldwell, T.M., De, L.S., Hodgetts, K.J., Yoon, T., Zheng, X. Substituted quinazolin-4-ylamine analogs as modulators of capsaicin. WO2003062209 (2003).
159. Eid SR. Therapeutic targeting of TRP channels--the TR(i)P to pain relief. Curr Top Med Chem 2011; 11: 2118-30.
160. Bayburt, E., Gomtsyan, A., Koenig, J., Lee, C.-H. Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor. US2004254188 (2004).
161. Gomtsyan A, Bayburt EK, Schmidt RG, Surowy CS, Honore P, Marsh KC, et al. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management. J Med Chem 2008; 51: 392-5.
162. Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, et al. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther 2008; 326: 879-88.
163. Othman AA, Nothaft W, Awni WM, Dutta S. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: Population analysis of data from 3 phase 1 trials. J Clin Pharmacol 2012; 52: 1028-41.
164. Othman AA, Nothaft W, Awni WM, Dutta S. Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/ pharmacodynamic analysis of three phase 1 trials. Br J Clin Pharmacol 2013; 75: 1029-40.
165. Faltynek, C.R., Gomtsyan, A.R., Honore, M.P., Jarvis, M.F., Joshi, S.K., Kort, M.E., Kym, P.R., Neelands, T.R., Reilly, R.M., Surowy, C.S. Repeated dosing of TRPV1 antagonists. US20100210682 (2010).
166. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 2009; 78: 211-6.
167. Gomtsyan, A., Daanen, J.F., Gfesser, G.A., Kort, M.E., Lee, C.-H., McDonald, H.A., Puttfarcken, P.S., Voight, E.A., Kym, P.R. TRPV1 antagonists. US20120245163 (2012).
168. Bayburt, E.K., Chen, J., Daanen, J.F., Didomenico, S. Jr., Gomtsyan, A.R., Kort, M.E., Kym, P.R., Mcdonald, H.A., Perner, R.J., Schmidt, R.G., Voight, E.A. Trpv1 antagonists. EP2352726 and EP2352727 (2011).
169. Bayburt, E.K., Daanen, J.F., Gomtsyan, A.R., Latshaw, S.P., Lee, C.-H., Schmidt, R.G. Jr., Antagonists of the trpv1 receptor and uses thereof. US20120022103 (2012).
170. Bayburt, E.K., Daanen, J.F., Gomtsyan, A.R., Latshaw, S.P., Lee, C.-H., Schmidt, R.G. Jr. Antagonists of the trpv1 receptor and uses thereof. US20120022103 (2012).
171. Daanen, J.F., Gfesser, G.A., Gomtsyan, A., Kort, M.R., Kym, P., Lee, C.-H., Mcdonald, H.A., Puttfarcken, P.S., Voight, E.A. Trpv1 antagonists. WO2012134943 (2012).
172. Gomtsyan, A.R., Schmidt, R.G., Daanen, J.F., Bayburt, E.K., Lee, C.-H., Latshaw, S.P. Antagonists of the TRPV1 receptor and uses thereof. EP2450346 (2012).
173. Gomtsyan, A.R., Voight, E.A., Bayburt, E.K., Chen, J., Daanen, J.F., Didomenico, S. Jr., Kort, M.E., Kym, P.R., Mcdonald, H.A., Perner, R.J., Schmidt, R.G. Trpv1 antagonists. WO2010045401 and WO2010045402 (2010).
174. Gomtsyan, A.R., Schmidt, R.G., Erol, K. Bayburt, E.K., Daanen, J.F., Kort, M.E. Trpv1 antagonists. US20100137360 (2010).
175. Gomtsyan, A.R., Bayburt, E.K., Chen, J., DiDomenico, S., Daanen, J.F., Kort, M.E., Kym, P.R., McDonald, H.A., Perner, R.J., Schmidt, R.G., Voight, E.A. Trpv1 antagonists. US20100120846 (2010).
176. Gomtsyan, A.R., Voight, E.A., Bayburt, E.K., Chen, J., Daanen, J.F., DiDomenico, S., Kort, M.E., Kym, P.R., McDonald, H.A., Perner, R.J., Schmidt, R.G. Trpv1 antagonists. US20100120846 (2010).
177. Lee, C.-H., Perner, R.J., Brown, B.S., Darbyshire, J. Compounds that inhibit TRPV1 and uses thereof. US20100249203 (2010).
178. Bayburt, E.K., Daanen, J.F., Didomenico, S. Jr., Gomtsyan, A.R., Koenig, J.R., Kort, M.E., Kym, P.R., Perner, R.J., Schmidt, R.G., Vasudevan, A., Voight, E. 2-aminooxazole derivatives as trpvl antagonists useful for treating pain. WO2009055749 (2009).
179. Bayburt, E.K., Daanen, J.F., Didomenico, S. Jr., Gomtsyan, A.R., Koenig, J.R., Kort, M.E., Kym, P.R., Perner, R.J., Schmidt, R.G., Vasudevan, A., Voight, E. 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases. EP2412372 (2012).
180. Brown, B.S., Daanen, J.F., Gomtsyan, A.R., Jinkerson, T.K., Keddy, R.G., Kort, M.E., Kym, P.R., Mark, A., Matulenko, M.A., Vasudevan, A. Amide derivatives as trpv1 antagonists. US20110288129. (2011).
181. De Petrocellis L, Schiano Moriello A, Fontana G, Sacchetti A, Passarella D, Appendino G, et al. Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogs at TRPV1 channels. Br J Pharmacol 2013 [Epub ahead of print].
182. Haight, A.R., Kotecki, B.J., Lukin, K.A., Wang, L., Yu, S. Methods for making central nervous system agents that are TRPV1 antagonists. EP2489660 (2012).
183. Lukin, K.A., Kotecki, B.J., Yu, S., Wang, L., Haight, A.R. Methods for making central nervous system agents that are TRPV1 antagonists. US8232411, EP2323989 and WO2009117626 (2012).
184. Woller, K.R., Gfesser, G.A., Liu, H., Daanen, J.F., Voight, E.A., Drizin, I.I., Shrestha, A., Mortell, K.H., Kym, P.R., Kort, M.E., Gomtsyan, A. TRPV1 antagonists. US20130158067 and WO2013096223 (2013).
185. Dart, M.J., Kym, P.R., Voight, E.A., Shrestha, A., Daanen, J.F., Jinkerson, T.K., Keddy, R.G., Peddi, S., Gomtsyan, A., Kort, M.E., Gfesser, G.A., Woller, K.R., Nelson, D.W. Trpv1 antagonists. US20130172334 (2013).
186. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00969787 (Accessed on: November 25, 2013).
187. Hori, Y., Koga, Y., Kondo, W., Matsuo, T., Ozeki, H., Sakata, M., Watanabe, T., Yamasaki, T., Yata, S. Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor. WO2006006741 (2006).
188. Laurent, D., Evanno, Y., Malanda, A. N(arylalkyl)-1hpyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof. WO2007010138 (2007).
189. Cox, M., Duncton, M., Fang, Y., Janagani, S., Kaub, C.J., Kelly, M.G., Kincaid, J., Sahasrabudhe, K., Upasani, R.B., Wei, Z.-L., Wu, G. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same. WO2007100758 (2007).
190. Hanazawa, T., Nagayama, S., Nakao, K., Shishido, Y., Tanaka, H. Cyclopropanecarboxamide compound. WO2007129188 (2007).
191. Maher MP, Bhattacharya A, Ao H, Swanson N, Wu NT, Freedman J, et al. Characterization of 2-(2,6-dichloro-benzyl)-thiazolo [5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine (JNJ 39729209) as a novel TRPV1 antagonist. Eur J Pharmacol 2011; 663: 40-50.
192. Napoletano, M., Trevisani, M., Pavani, M.G., Fruttarolo, F. Trpv1 vanilloid receptor antagonists with a bicyclic portion. US20130079339 and WO2011120604 (2013).
193. Web site of Pharmeste, a private biopharmaceutical company focused on the discovery and development of Transient Receptor Potential (TRP) channel therapeutics for the treatment of neuropathic pain, and other TRP-mediated diseases. Available at: http://www.pharmeste.com/repository/contenuti/paragrafi/file/Phar mEste_Leaflet_Web.pdf (Accessed on: November 25, 2013).
194. Uchida, H. 2-indoleacrylamide analogue. WO2010038803 (2010).
195. Uchida, H., Ogawa, S., Makabe, M., Maeda, Y. Heterocyclidene-n-(3,4-dihydro-2(1h)-quinazolin-5-yl) acetamide derivative. WO2010010933 (2010).
196. Uchida, H. Optically active heterocyclidene-n-arylacetamide derivative. WO2010010935 (2010).
197. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/show/NCT00960180 (Accessed on: November 25, 2013).
198. Uchida, H., Kosuga, N., Satoh, T., Hotta, D., Kamino, T., Maeda, Y., Amano, K.-I., Akada, Y. Novel heterocyclidene acetamide derivative. WO2007010383 (2007).
199. Brain, C.T., Culshaw, A.J., Dziadulewicz, E.K., Ritchie, T.J. Quinazolinone derivatives as vanilloid antagonists. EP1978967 (2010).
200. Branstetter, B.J., Breitenbucher, J.G., Lebsack, A.D., Liu, J., Rech, J.C., Xiao, W. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1. US20130005687 (2013).
201. Abouabdellah, A., Burnier, P., Hoornaert, C., Jeunesse, J., Puech, F. Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of the same in therapeutics. US7214798 (2007).
202. Dasse, O. Combination FAAH inhibitor and analgesic, antiinflammatory or anti-pyretic agents. WO2008021625 (2008).
203. Dasse, O., Putman, D., Compton, T.R., Parrott, J.A. Metabolicallystabilized inibitors of fatty acid amide hydrolase. WO2008063714 (2008).
204. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996; 384: 83-7.
205. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001; 98: 9371-6.
206. Boger, D.L. Inhibitors of fatty acid amide hydrolase. US6462054 (2002).
207. Lambert DM, Fowler CJ. The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48: 5059-87.
208. Gilula, N.B., Cravatt, B.F., Lerner, R.A. Fatty-acid amide hydrolase. US7348173 (2008).
209. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-9.
210. Di Marzo V, Bisogno T, De Petrocellis L. Anandamide: Some like it hot. Trends Pharmacol Sci 2001; 22: 346-9.
211. Van Der Stelt M, Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004; 271: 1827-34.
212. Zimov S, Yazulla S. Vanilloid receptor 1 (TRPV1/VR1) colocalizes with fatty acid amide hydrolase (FAAH) in retinal amacrine cells. Vis Neurosci 2007; 24: 581-91.
213. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003; 140: 790-801.
214. Ahluwalia J, Yaqoob M, Urban L, Bevan S, Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 2003; 84: 585-91.
215. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007; 150: 766-81.
216. De Novellis, V., De Petrocellis, L., Di Marzo, V., Maione, S. Method for treating pain. WO2007047820 (2007).
217. Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, et al. New N-arachidonoylserotonin analogs with potential "dual" mechanism of action against pain. J Med Chem 2007; 50: 6554-69.
218. Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008; 8: 247-67.
219. Morera E, De Petrocellis L, Morera L, Moriello AS, Ligresti A, Nalli M, et al. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett 2009; 19: 6806-9.
220. Ortar G, De Petrocellis L, Moriello AS, Allarà M, Morera E, Nalli M, et al. Tetrahydro-_-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorg Med Chem Lett 2013; 23: 138-42.
221. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 2005; 48: 1857-72.
222. De Petrocellis L, Di Marzo V. Role of endocannabinoids and endovanilloids in Ca2+ signalling. Cell Calcium 2009; 45: 611-24.
223. Casillas RP, Mitcheltree LW, Stemler FW. The mouse ear model of cutaneous sulfur mustard injury. Toxicol Methods 1997; 7: 381-97.
224. Casillas RP, Kiser RC, Truxall JA, Singer AW, Shumaker SM, Niemuth NA, et al. Therapeutic approaches to dermatotoxicity by sulfur mustard. I. Modulaton of sulfur mustard-induced cutaneous injury in the mouse ear vesicant model. J Appl Toxicol 2000; 20: S145-51.
225. Messeguer A, Planells-Cases R, Ferrer-Montiel A. Physiology and pharmacology of the vanilloid receptor. Curr Neuropharmacol 2006; 4: 1-15.
226. Fowler CJ, Naidu PS, Lichtman A, Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br J Pharmacol 2009; 156: 412-9.
227. Laskin, J.D., Heck, D.E., Lacey, C.J., Aponte, E., Huang, M.-T., Heindel, N.D. Pharmacologically-active vanilloid carbamates. US8343971 (2013).
228. Frank, R., Schick, H., Sundermann, B. Pentafluorosulphanylsubstituted compound and its use for producing medicaments. US7994167 (2011).
229. Frank, R., Bahrenberg, G., Christoph, T., Lesch, B., Lee, J. Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands. WO2013045447 (2013).
230. Frank, R., Bahrenberg, G., Christoph, T., Lesch, B., Lee, J. Amine substituted methanesulfonamide derivatives as vanilloid receptor ligands. WO2013045451 (2013).
231. Bahrenberg, G., Christoph, T., De Vry, J., Frank, R., Lee, J., Saunders, D., Schiene, K., Sundermann, B. Vanilloid Receptor Ligands, Pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions. US20090156590 and US20110301156 (2011).
232. Frank, R., Haurand, M., Hennies, H.-H., Hinze, C., Jostock, R., Schiene, K. Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs. EP1891035 (2011).
233. Frank, R., Bahrenberg, G., Christoph, T., Schiene, K., De Vry, J., Damann, N., Frormann, S., Lesch, B., Lee, J., Kim, Y.-S., Kim, M.-S. Substituted phenylureas and phenylamides as vanilloid receptor ligands. WO2010127856 (2010).
234. Frank, R., Christoph, T., Damann, N., Lesch, B., Bahrenberg, G., Saunders, D.J., Stockhausen, H., Kim, Y.-S., Kim, M.-S., Lee, J. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-cyclic group as vanilloid receptor ligands. WO2013068463 and WO2013068467 (2013).
235. Frank, R., Christoph, T., Schiene, K., De Vry, J., Damann, N., Lesch, B., Bahrenberg, G., Saunders, D.J., Stockhausen, H., Kim, Y.-S., Kim, M.-S., Lee, J. Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an ocontaining group as vanilloid receptor ligands. WO2013068461 (2013).
236. Frank, R., Bahrenberg, G., Christoph, T., Lesch, B. Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands. WO2013013815 and US20130029962 (2013).
237. Frank, R., Christoph, T., Lesch, B., Lee, J. Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands. WO2013013816 (2013).
238. Kim MS, Ryu H, Kang DW, Cho SH, Seo S, Park YS, et al. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: Structureactivity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region. J Med Chem 2012; 55: 8392-408.
239. Thorat SA, Kang DW, Ryu H, Kim MS, Kim HS, Ann J, et al. 2-(3-Fluoro-4 methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists: Structure activity relationships of the 2-oxy pyridine C-region. Eur J Med Chem 2013; 64: 589-602.
240. Jeong, Y.S., Kim, H.-D., Kim, J.K., Kim, S.-Y., Lee, K.-W., Oh, U.T., Park, H.-G., Park, Y.-H., Shin, S.S., Suh, Y.-G., Woo, B.Y. Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same. WO2007142426 (2007).
241. Choi, J.K., Jeong, Y.S., Kim, D.H., Kim, H., Kim, J.-S., Kim, J.K., Kim, S.-Y., Kim, Y., Koh, H.-J., Lee, J., Lee, K.-W., Li, F., Lim, K.M., Moh, J.-H., Shin, S.S., Suh, Y.-G., Woo, B.Y., Yoon J.H. Sulphonamides as vanilloid receptor antagonist. EP20090773745 (2009).
242. Shin, S.S., Kim, J.K., Kim, S.-Y., Lee, K.-W., Woo, B.Y., Moh, J.-H., Jeong, Y.S., Lim, K.M., Choi, J.K., Koh, H.-J., Park, Y.-H. Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same. US20110015230 (2011).
243. Woo, B.Y., Kim, S.-Y., Kim, Y., Shin, S.S., Kim, J.K., Lee, K.-W., Kim, D.H., Lim, K.M., Moh, J.-H., Jeong, Y.S., Choi, J.K., Koh, H.-J., Lee, J., Kim, H., Yoon, J.H., Li, F., Kim, J.-S., Suh, Y.-G. Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same. US20110152318 (2011).
244. Tafesse, L. TRPV1 antagonists including dihydroxy substituent and uses thereof. US8476277 (2013).
245. Yu, J. TRPV1 antagonists including dihydroxy substituent and uses thereof. WO2013021276 (2013).
246. Vidal-Mosquera M, Fernández-Carvajal A, Moure A, Valente P, Planells-Cases R, González-Ros JM, et al. Triazine-based vanilloid 1 receptor open channel blockers: Design, synthesis, evaluation, and SAR analysis. J Med Chem 2011; 54: 7441-52.
247. Ferrer-Montiel, A., Fernández-Carvajal, A., Gonzales-Ros, J.M., Belmonte, M.C., Viana, F., Gomis-Garcia, A., Messenguer, P.A., Bujons-Vilas, J., Vidal-Mosquera, M., Planells-Cases, R. Triazine derivatives and their uses as trpv1 inhibitors. WO2012136873 (2012).
248. Valente P, Fernández-Carvajal A, Camprubí-Robles M, Gomis A, Quirce S, Viana F, et al. Membrane-tethered peptides patterned after the TRP domain (TRPducins) selectively inhibit TRPV1 channel activity. FASEB J 2011; 25: 1628-40.
249. Ponsati B, Carreño C, Curto-Reyes V, Valenzuela B, Duart MJ, Van den Nest W, et al. An inhibitor of neuronal exocytosis (DD04107) displays long-lasting in vivo activity against chronic inflammatory and neuropathic pain. J Pharmacol Exp Ther 2012; 341: 634-45.
250. Christoph T, Bahrenberg G, De Vry J, Englberger W, Erdmann VA, Frech M, et al. Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell Neurosci 2008; 37: 579-89.
251. Acosta Boj, M.C., Gallar Martinez, J., Yague, A.S., Belmonte Martinez, C., Jimenez Anton, A., Jimenez Gomez, M.C. Modulation of trpv expression levels. US8354385 (2013).
252. French, P.W., Graham, M.W. Pain treatment. WO2013126963 (2013).
253. Mori F, Ribolsi M, Kusayanagi H, Monteleone F, Mantovani V, Buttari F, et al. TRPV1 channels regulate cortical excitability in humans. J Neurosci 2012; 32: 873-9.
254. Giordano C, Cristino L, Luongo L, Siniscalco D, Petrosino S, Piscitelli F, et al. TRPV1-dependent and-independent alterations in the limbic cortex of neuropathic mice: Impact on glial caspases and pain perception. Cereb Cortex 2012; 22: 2495-518.
255. Aguiar DC, Terzian AL, Guimarães FS, Moreira FA. Anxiolyticlike effects induced by blockade of transient receptor potential vanilloid type 1 channels in the medial prefrontal cortex of rats. Psychopharmacol 2009; 205: 217-25.
256. Moreira FA, Wotjak CT. Cannabinoids and anxiety. Curr Top Behav Neurosci 2010; 2: 429-50.
257. Laricchiuta D, Centonze D, Petrosini L. Effects of endocannabinoid and endovanilloid systems on aversive memory extinction. Behav Brain Res 2013; 256C: 101-7.
258. Connors, B.W., Gibson, H.E., Kauer, J.A., Kim, J.A. Treatment and prophylaxis of epilepsy and febrile seizures. US20110166196 (2011).
259. Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M. Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 2006; 147: 552-9.
260. Sun FJ, Guo W, Zheng DH, Zhang CQ, Li S, Liu SY, et al. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy. J Mol Neurosci 2013; 49: 182-93.
261. Chen CY, Li W, Qu KP, Chen CR. Piperine exerts anti-seizure effects via the TRPV1 receptor in mice. Eur J Pharmacol 2013; 714: 288-94.
262. Jones, K.W., Ren, X., Weintraub, N.L. Methods of preventing ischemic injury using peripheral nociceptive stimulation. WO2012060845 (2012).
263. Krüger, C., Laage, R., Moraru, A., Pitzer, C., Schneider, A. Use of piperine and derivatives thereof for the therapy of neurological conditions. US20100179130 (2010).
264. Kauer JA, Gibson HE. Hot flash: TRPV channels in the brain. Trends Neurosci 2009; 32: 215-24.
265. Matta JA, Ahern GP. TRPV1 and synaptic transmission. Curr Pharm Biotechnol 2011; 12: 95-101.
266. Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L, et al. Polymodal activation of the endocannabinoid system in the extended amygdala. Nat Neurosci 2011; 14: 1542-7.
267. Musella A, De Chiara V, Rossi S, Prosperetti C, Bernardi G, Maccarrone M, et al. TRPV1 channels facilitate glutamate transmission in the striatum. Mol Cell Neurosci 2009; 40: 89-97.
268. Starowicz K, Cristino L, Di Marzo V. TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr Pharm Des 2008; 14: 42-54
269. Kissin I, Szallasi A. Therapeutic targeting of TRPV1 by resiniferatoxin, from preclinical studies to clinical trials. Curr Top Med Chem 2011; 11: 2159-70.
270. Engel MA, Izydorczyk I, Mueller-Tribbensee SM, Becker C, Neurath MF, Reeh PW. Inhibitory CB1 and activating/ desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides 2011; 45: 229-37.
271. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006; 316: 969-82.
272. Kawahara H, Drew GM, Christie MJ, Vaughan CW. Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br J Pharmacol 2011; 163: 1214-22.
273. Liao HT, Lee HJ, Ho YC, Chiou LC. Capsaicin in the periaqueductal gray induces analgesia via metabotropic glutamate receptormediated endocannabinoid retrograde disinhibition. Br J Pharmacol 2011; 163: 330-45.
274. Pospisilova E, Palecek J. Post-operative pain behaviour in rats is reduced after single high-concentration capsaicin application. Pain 2006; 125: 233-43.
275. Kissin I. Vanilloid-induced conduction analgesia: Selective, dosedependent, long-lasting, with a low level of potential neurotoxicity. Anesth Analg 2008; 107: 271-81.
276. Fischer MJ, Leffler A, Niedermirtl F, Kistner K, Eberhardt M, Reeh PW, et al. The general anesthetic propofol excites nociceptors by activating TRPV1 and TRPA1 rather than GABAA receptors. J Biol Chem 2010; 285: 34781-92.
277. Ji W, Cui C, Zhang Z, Liang J. Paradoxic effects of propofol on visceral pain induced by various TRPV1 agonists. Exp Ther Med 2013; 5: 1259-63.
278. Takechi K, Carstens MI, Klein AH, Carstens E. The antinociceptive and antihyperalgesic effects of topical propofol on dorsal horn neurons in the rat. Anesth Analg 2013; 116: 932-8.
279. Matta JA, Cornett PM, Miyares RL, Abe K, Sahibzada N, Ahern GP. General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci USA 2008; 105: 8784-9.
280. Vanden Abeele F, Kondratskyi A, Dubois C, Shapovalov G, Gkika D, Busserolles J, et al. Complex modulation of the cold receptor TRPM8 by volatile anaesthetics and its role in complications of general anaesthesia. J Cell Sci 2013; 126: 4479-89.
281. Cornett PM, Matta JA, Ahern GP. General anesthetics sensitize the capsaicin receptor transient receptor potential V1. Mol Pharmacol 2008; 74: 1261-8.
282. ClinicalTrials. gov A service of the U.S. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/results?term= propofol+ postoperative+pain&Search=Search (Accessed on: November 26, 2013).